ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
otherperspective
|
567 |
211K |
110 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
567
|
211K
|
110
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
52 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
17K
|
6.6M
|
52
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Grants Orphan Drug Designation for Revascor
|
|
otherperspective
|
272 |
98K |
47 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
272
|
98K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
otherperspective
|
551 |
197K |
60 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
551
|
197K
|
60
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
otherperspective
|
551 |
197K |
94 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
551
|
197K
|
94
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Placement and Entitlement Offer
|
|
otherperspective
|
154 |
45K |
49 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
154
|
45K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
otherperspective
|
549 |
170K |
64 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
170K
|
64
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
otherperspective
|
549 |
170K |
73 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
170K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
otherperspective
|
549 |
170K |
84 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
549
|
170K
|
84
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Half Year Financial Results Presentation
|
|
otherperspective
|
78 |
23K |
77 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
78
|
23K
|
77
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
9.5K |
2.7M |
82 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
82
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
9.5K |
2.7M |
63 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
63
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
otherperspective
|
9.5K |
2.7M |
59 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
9.5K
|
2.7M
|
59
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
otherperspective
|
512 |
123K |
49 |
01/01/24 |
01/01/24 |
ASX - By Stock
|
512
|
123K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Institutional Placement and Entitlement Offer
|
|
otherperspective
|
512 |
123K |
70 |
31/12/23 |
31/12/23 |
ASX - By Stock
|
512
|
123K
|
70
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
otherperspective
|
716 |
198K |
71 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
716
|
198K
|
71
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Files for FDA Designations in Congenital Heart Disease
|
|
otherperspective
|
68 |
22K |
92 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
68
|
22K
|
92
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
57 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
17K
|
6.6M
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Annual Report to Shareholders
|
|
otherperspective
|
74 |
24K |
89 |
30/10/23 |
30/10/23 |
ASX - By Stock
|
74
|
24K
|
89
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
otherperspective
|
574 |
191K |
23 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
574
|
191K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Type A Meeting with FDA
|
|
otherperspective
|
574 |
191K |
104 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
574
|
191K
|
104
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
42 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
42
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Annual Financial Results and Operational Update
|
|
otherperspective
|
60 |
24K |
61 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
60
|
24K
|
61
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
275K |
70 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
904
|
275K
|
70
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
275K |
74 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
904
|
275K
|
74
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
275K |
50 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
904
|
275K
|
50
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
otherperspective
|
904 |
275K |
53 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
904
|
275K
|
53
|
|
ASX - By Stock
|
MSB |
Re:
The FDA is a corrupt organization.
|
|
otherperspective
|
155 |
56K |
173 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
155
|
56K
|
173
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
otherperspective
|
39 |
18K |
73 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
39
|
18K
|
73
|
|
ASX - By Stock
|
MSB |
Re:
How will you celebrate when FDA gives the Tick
|
|
otherperspective
|
82 |
37K |
57 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
82
|
37K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
55 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
55
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
98 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
98
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
106 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
106
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
otherperspective
|
3.4K |
1.1M |
86 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
86
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
57 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
17K
|
6.6M
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
128 |
19/07/23 |
19/07/23 |
ASX - By Stock
|
17K
|
6.6M
|
128
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Third Quarter Results Presentation
|
|
otherperspective
|
55 |
21K |
62 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
55
|
21K
|
62
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
17K |
6.6M |
97 |
25/05/23 |
25/05/23 |
ASX - By Stock
|
17K
|
6.6M
|
97
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Private Placement
|
|
otherperspective
|
71 |
36K |
115 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
71
|
36K
|
115
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
otherperspective
|
275 |
110K |
57 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
275
|
110K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection
|
|
otherperspective
|
275 |
110K |
114 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
275
|
110K
|
114
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
1.0K |
383K |
65 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
383K
|
65
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
1.0K |
383K |
83 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
383K
|
83
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
otherperspective
|
1.0K |
383K |
124 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
383K
|
124
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Second Quarter Results Presentation
|
|
otherperspective
|
117 |
29K |
51 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
117
|
29K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Second Quarter Results Presentation
|
|
otherperspective
|
117 |
29K |
51 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
117
|
29K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Second Quarter Results Presentation
|
|
otherperspective
|
117 |
29K |
57 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
117
|
29K
|
57
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
otherperspective
|
914 |
286K |
75 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
914
|
286K
|
75
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel Clinical and Potency Studies Presented at Tandem
|
|
otherperspective
|
217 |
69K |
69 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
217
|
69K
|
69
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
otherperspective
|
914 |
286K |
72 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
914
|
286K
|
72
|
|